^
    Back
    Association details:
    Biomarker:FGFR1 fusion
    Cancer:Pancreatic Cancer
    Drug:Balversa (erdafitinib) (pan-FGFR inhib)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial

    Published date:
    10/16/2023
    Excerpt:
    Responses were observed in pts with FGFR1 and FGFR2 fusions….Erda demonstrated robust and clinically meaningful activity in pancreatic cancer pts with FGFRalt.
    Trial ID:
    RAGNAR